Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03709823 · ClinicalTrials.gov registry record · Phase 2
Trial of Cytisine in Adult Smokers
A Phase 2 study, sponsored by Achieve Life Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT03709823: Completed Phase 2 study, sponsored by Achieve Life Sciences.
NCT03709823 is a Phase 2 study that has completed, run by Achieve Life Sciences. The registered enrollment target is 254 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03709823, a Phase 2 study, has completed, sponsored by Achieve Life Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.
Primary Outcome
The daily cigarette counts (number of cigarettes smoked in the past 24 hours) were self-reported by participants in the diary. Percentage of expected cigarettes smoked was computed for each participant at the end of treatment (cigarette score), based on daily cigarette counts during treatment vs the screening period. The percentage of expected cigarettes smoked was computed as Y = (100 x N) / (T x R) where N represents total number of cigarettes smoked each day over the treatment period from Day
Interventions
- DRUG Placebo Comparator
- BEHAVIORAL Behavioral support
- DRUG Cytisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2019-04-23 |
| Phase | Phase 2 |
What the finished NCT03709823 record still lists
NCT03709823 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT03709823 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03709823 about?
NCT03709823 is a clinical study titled "Trial of Cytisine in Adult Smokers". This placebo-controlled Phase 2b trial is being conducted at sites within the United States (US) to evaluate the effectiveness cytisine dosage (1.5 mg, 3.0 mg) and administration schedule (commercial titration versus simplified 3 times daily \[TID\] schedule) within a 25-day treatment period.
What is the current status of trial NCT03709823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2018-11-13. Estimated completion is 2019-04-23.
What interventions are being tested in trial NCT03709823?
The interventions under investigation include: Placebo Comparator (DRUG), Behavioral support (BEHAVIORAL), Cytisine (DRUG).
Who is sponsoring clinical trial NCT03709823?
This trial is sponsored by Achieve Life Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03709823's enrollment target sits among peer trials
254 219th of 2000 higher than 1,781 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI